Standard
Johnson & Johnson Medtech Performance Faces Headwinds as Cardiovascular Growth Stalls Amid Abiomed Clinical Trial Scrutiny
The global healthcare landscape watched closely as Johnson & Johnson (J&J) released its third-quarter financial results, revealing a Medtech segment that, while growing, failed to meet the ambitious internal benchmarks set by the New Jersey-based conglomerate. For the period ending September 30, the medical technology division reported total sales of $8.64 billion, marking a 2.5%…
